Graham Jackson

Active 1976–2025

154
Papers
25,060
Citations
95
h-index
153
i10-index

Citations

Citations per year for Graham Jackson1978: 1 citations1980: 2 citations1981: 4 citations1982: 4 citations1983: 6 citations1984: 7 citations1985: 11 citations1986: 6 citations1987: 6 citations1988: 5 citations1989: 5 citations1990: 8 citations1991: 10 citations1992: 6 citations1993: 4 citations1994: 7 citations1995: 11 citations1996: 8 citations1997: 9 citations1998: 13 citations1999: 19 citations2000: 26 citations2001: 44 citations2002: 64 citations2003: 74 citations2004: 87 citations2005: 102 citations2006: 133 citations2007: 103 citations2008: 86 citations2009: 99 citations2010: 126 citations2011: 127 citations2012: 201 citations2013: 215 citations2014: 155 citations2015: 142 citations2016: 150 citations2017: 182 citations2018: 150 citations2019: 621 citations2020: 751 citations2021: 731 citations2022: 582 citations2023: 359 citations2024: 720 citations2025: 264 citations2026: 3 citations1979: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,044 citing papers, 23.1% of this breakdownUnited Kingdom: 863 citing papers, 9.8% of this breakdownItaly: 573 citing papers, 6.5% of this breakdownGermany: 532 citing papers, 6% of this breakdownFrance: 422 citing papers, 4.8% of this breakdownChina: 419 citing papers, 4.7% of this breakdownSpain: 332 citing papers, 3.7% of this breakdownCanada: 306 citing papers, 3.5% of this breakdownNetherlands: 300 citing papers, 3.4% of this breakdownAustralia: 263 citing papers, 3% of this breakdownSwitzerland: 194 citing papers, 2.2% of this breakdownGreece: 191 citing papers, 2.2% of this breakdown
0%23.1%Other 27.1%

Fields

  • Medicine78%
  • Biochemistry, Genetics and Molecular Biology14%
  • Immunology and Microbiology4.3%
  • Computer Science0.7%
  • Psychology0.7%
  • Health Professions0.3%
  • Other2%

Topics

  • Multiple Myeloma Research and Treatments9.5%
  • Protein Degradation and Inhibitors4.8%
  • Sexual function and dysfunction studies4.2%
  • Hormonal and reproductive studies3%
  • Hematopoietic Stem Cell Transplantation2.7%
  • Acute Myeloid Leukemia Research2.3%
  • Other73.5%

Coauthors

All papers

Open in search
  1. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 cited by 407

  2. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Leukemia 2018 cited by 453

  3. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Blood 2018 cited by 495

  4. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 564

  5. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc S. Raab, Fritz Van Rhee, Saad Z. Usmani, Kenneth H. Shain, Niels Weinhold, Gareth J. Morgan, Ola Landgren - Journal of Clinical Oncology 2024 cited by 119

  6. A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease

    Authors: , , , , , , - European Urology 2013 cited by 528

  7. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 110

  8. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lionel Karlin, Thierry Façon, Michel Attal, Katja Weisel, Monika Engelhardt, Andréas Mackensen, John Quinn, Irit Avivi, Amos Cohen, Hila Magen‐Nativ, Noam Benyamini, Michèle Cavo, Alessandra Larocca, Naoki Takezako, Kenshi Suzuki, Hiroshi Kosugi, Morio Matsumoto, Shinsuke Iida, Takayuki Ishikawa, Yukio Kondo, Kazutaka Sunami, Kiyoshi Ando, Takanori Teshima, Takaaki Chou, Hiromi Iwasaki, Hirokazu Miki, Itaru Matsumura, Yasushi Onishi, Koji Izutsu, Masahiro Kizaki, Anupkumar George, Hillary Blacklock, David Simpson, Fredrik Schjesvold, Anders Waage, Olga Samoilova, Evgeniy Nikitin, Tatiana Chagorova, Andrew M. McDonald, Moosa Patel, Albert Oriol, Jesus San Miguel Izquierdo, María‐Victoria Mateos, Matthew Streetly, Peter Forsyth, Graham Jackson, Stephen J. Jenkins, Robert M. Rifkin, Habte Yimer, Robert McCroskey, Danko Martincic, Stefano Tarantolo, Sarah Larson, Yacoub Faroun, Jennifer Vaughn, Rachid Baz, Gene Saylors, Amarendra Neppalli, Anastasios Raptis, Henry C. Fung, Maxwell Janosky, Don A. Stevens, Morton Coleman, Dennis Costa, Scott Cross, Suzanne Fanning, Daniel Farray Berges, Thomas M. Harris, Ira Zackon, Djordje Atanackovic and 17 more - The Lancet Haematology 2019 cited by 242

  9. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2017 cited by 235

  10. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 340

  11. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 cited by 318

  12. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 85

  13. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

    Authors: , , , , , , , , , , , , , , , - Leukemia 2011 cited by 346

  14. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

    Authors: , , , , , , , , , , , , , , , , , - Haematologica 2021 cited by 85

  15. Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes

    Authors: , , , , , , , , , - Diabetes Care 2011 cited by 365

  16. Burkitt's lymphoma

    Authors: , , , , , , , , - The Lancet 2012 cited by 604

  17. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva - Leukemia 2020 cited by 119

  18. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review

    Authors: , , , , , , , , , , , , , , , - Blood Cancer Journal 2023 cited by 68

  19. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - Mayo Clinic Proceedings 2012 cited by 464

  20. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sara Bringhen, Pieter Sonneveld - Leukemia 2020 cited by 149

  21. Ikaros family zinc finger 1 regulates dendritic cell development and function in humans

    Authors: , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 81

  22. Donor monocyte–derived macrophages promote human acute graft-versus-host disease

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2020 cited by 69

  23. Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

    Authors: , , , , , , , - Journal of the American College of Cardiology 2005 cited by 356

  24. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hareth Nahi, Sven Nelander, Jolanta Nickel, Markus M. Nöthen, Þórunn Rafnar, Fiona M. Ross, Miguel Inácio da Silva Filho, Bhairavi Swaminathan, Hauke Thomsen, Ingemar Turesson, Annette Juul Vangsted, Ulla Vogel, Anders Waage, Brian A. Walker, Anna-Karin Wihlborg, Annemiek Broyl, Faith E. Davies, Unnur Þorsteinsdóttir, Christian Langer, Markus Hansson, Martin Kaiser, Pieter Sonneveld, Kāri Stefánsson, Gareth J. Morgan, Hartmut Goldschmidt, Kari Hemminki, Björn Nilsson, Richard S. Houlston - Nature Communications 2016 cited by 182